builderall

CONFERENCE INFORMATION

Conference Description

This master lecture series will provide the most up-to-date, practical information on the management of breast cancer, lung cancer, gastrointestinal, genitourinary and melanoma in 2025. Immunotherapy and target therapies will be discussed in personalized therapy, and the latest clinical data impacting the treatment of these cancers.  We will discuss the most current data in GI (circulating tumor DNA, next generation sequencing, and molecular drive mutations), GU (PARP Inhibitors), Lymphoma (Chronic Lymphocytic Leukemia, Follicular Lymphoma), Lung (RET/MET/VEGFR2) and breast cancer (HER2 P13K/Akt/TROP2).

Cutting edge lectures, panel discussions, multidisciplinary tumor boards with lively and collaborative question-and-answer sessions will provide a unique opportunity for participants to interact with faculty as they share their viewpoints and personal practices on the clinical challenges and ongoing controversies in managing cancer patients. The audience will engage in case-based discussions and critical deliberations on the state of current knowledge, clinical findings, differential diagnoses, and management plan options for their patients.

Target Audience

This one-day program has been designed to meet the educational needs of health care professionals involved in the treatment of cancer. Medical oncologists, radiation oncologists, surgical oncologists, advanced registered nurse practitioners (ARNP), physician associates (PA), oncology nurses, registered pharmacists, pharmacy technicians, radiation therapists and general practitioners (internal medicine and family medicine) will have the benefit of a review of the standard of care and new developments in cancer therapy. Residents in training and fellows from these specialties will benefit from this program.

Learner Objectives

Upon completion of this activity, participants should be able to:

  • Employ an understanding of personalized medicine to individualize the use of available drugs in oncology.

  • Communicate the efficacy, safety and side effects of the drugs discussed in emerging treatments.

  • Describe current data on the efficacy and safety of tumor immunotherapy and consider this information when counseling patients regarding clinical trial participation.

  • Identify the emerging and standard diagnostic tests used to assist in planning therapy for their patients.

  • Formulate management strategies for lung, gastrointestinal, genitourinary and breast cancer, considering the contributory roles of local and systemic therapy.

  • Discuss current data on clinical trials evaluating novel investigational agents in lung, gastrointestinal, genitourinary and breast cancer to help clinicians counsel appropriately selected patients about availability and participation.